Sponsors (2)
The bill improves national and hospital access to critical medicines and bolsters domestic supply resilience through required reserves and funding, at the cost of increased federal spending, potential higher drug prices, and compliance burdens that may favor larger manufacturers and limit private inventory control.
Patients (including people with chronic conditions) and hospitals will face fewer critical‑drug shortages and more reliable access during emergencies because awardees must hold a multi‑month reserve and the Secretary can direct transfers/allocations.
The bill strengthens U.S. drug‑supply resilience by favoring domestic and OECD‑based manufacturing, reducing dependence on single foreign sources and improving national preparedness.
Provides federal funding (authorization of $500M for FY2026) to build reserves and potentially expand manufacturing capacity, supporting preparedness and manufacturing jobs.
Manufacturers' requirements to keep recent stock and regularly replenish reserves could raise operating costs, which may be passed on as higher drug prices affecting patients and health systems.
Smaller generic makers and some foreign suppliers that cannot meet domestic/OECD facility or surge‑capacity requirements may be excluded from awards, concentrating contracts among larger firms and reducing competition.
Taxpayers face higher federal spending or budget tradeoffs from the $500 million authorization and ongoing program costs.
Based on analysis of 2 sections of legislative text.
Authorizes HHS contracts/cooperative agreements to create and maintain rolling reserves of critical drugs and APIs, with transfer and allocation authority during emergencies.
Official title: To improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.
Introduced June 12, 2025 by Angela Craig · Last progress June 12, 2025
Creates a new HHS program to contract with eligible manufacturers to build and maintain a rolling domestic (or OECD-registered) reserve of critical drugs and their active pharmaceutical ingredients (APIs) with vulnerable supply chains. Awardees must hold a specified multi-month inventory, regularly replenish with recently manufactured supply, allow Secretary-directed transfers or allocations during emergencies, and meet quality, domestic-manufacturing, and surge-production requirements; HHS/FDA must issue implementing guidance within 180 days.